Skip to main content

Market Overview

The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering

Share:
The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering

Here's a roundup of top developments in the biotech space over the last 24 hours:

Scaling The Peaks

(Biotech stocks hitting 52-week highs on Feb. 12)

  • Abbott Laboratories (NYSE: ABT)
  • Amphastar Pharmaceuticals Inc (NASDAQ: AMPH)
  • Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN)
  • Boston Scientific Corporation (NYSE: BSX)
  • Edwards Lifesciences Corp (NYSE: EW)(CASM) for $100 million)
  • Masimo Corporation (NASDAQ: MASI)
  • Mirati Therapeutics Inc (NASDAQ: MRTX)

Down In The Dumps

(Biotech stocks hitting 52-week lows on Feb. 12)

  • CELLECT BIOTECH/S ADR (NASDAQ: APOP)
  • Collegium Pharmaceutical Inc (NASDAQ: COLL)
  • Organogenesis Holdings Inc (NASDAQ: ORGO)
  • Scpharmaceuticals Inc (NASDAQ: SCPH)

Stock In Focus

Exelixis Q4 Exceeds Expectations

Exelixis, Inc. (NASDAQ: EXEL) reported fourth-quarter non-GAAP EPS of 37 cents per share. Total revenues climbed from $120.1 million to $228.6 million, helped by strong Cabozantinib franchise net revenues, which climbed 84 percent year-over-year to $176.2 million. The results beat consensus estimates, which called for EPS of 24 cents on revenues of $188.76 million.

The stock rallied 7.38 percent to $23.28 in after-hours trading.

MacroGenics Price Of Common Stock Offering At A Discount

MacroGenics Inc (NASDAQ: MGNX) priced its public offering of 5.50 million shares at $20 per share. The company expects total proceeds from the offering of $110 million.

The stock slipped 1.62 percent to $20.65 in after-hours trading.

Vistagen Q3 Loss Wider Than Expected

Vistagen Therapeutics Inc (NASDAQ: VTGN), which has an investigational depression drug in its pipeline, reported a third-quarter loss of 24 cents per share compared to a loss of 25 cents per share a year ago. Analysts estimated a narrower loss of 22 cents per share.

The stock declined 3.41 percent to $1.70 in after-hours trading.

FDA Panel OKs J&J's Treatment-Resistant Depression Drug

Johnson & Johnson (NYSE: JNJ)'s Janssen unit said a joint meeting of FDA's Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee voted in favor of the benefit-risk profile of Esketamine nasal spray for adults with treatment-resistant depression, with 14 giving a thumbs up, 2 against and 1 member abstaining.

The PDUFA date for the pipeline asset is set for March 4.

See Also: Gilead Analysts React To Failed NASH Trial: Citigroup, Wells Fargo Downgrade Biotech

Moderna Reports Positive Early-Stage Results For Respiratory Infection Vaccine

Moderna Inc (NASDAQ: MRNA) announced positive topline results from the first planned interim analysis of safety and immunogenicity from a Phase 1 study of mRNA-1653 in healthy adults.

mRNA is being evaluated as a prophylactic vaccine against t human metapneumovirus (hMPV) and parainfluenza type 3 (PIV3), two viruses that cause respiratory infections, and is a combo vaccine that consists of two direct mRNA sequences encoding the fusion proteins of hMPV and PIV3 formulated in Moderna's proprietary lipid nanoparticle technology.

The interim results showed a single vaccination boosted serum neutralization titers against hMPV and PIV3, and that the magnitude of the boost was similar at all dose levels tested. The study also showed a single vaccination was sufficient to achieve a plateau in neutralizing antibodies in pre-exposed population. It was also found to be safe and generally well tolerated.

On The Radar

PDUFA Date

The FDA is set to rule on MOTIF BIO PLC/S ADR (NASDAQ: MTFB)'s NDA for Iclaprim to acute bacterial skin and skin structure infections, or ABSSSI.

Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) Q4 EPS $(0.10) Beats $(0.15) Estimate, Sales $130.69M Beat $98.47M Estimate
Natus Medical Inc (NASDAQ: BABY) Q4 Adj. EPS $0.43 Misses $0.49 Estimate, Sales $141M Beat $136.65M Estimate
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) (after the market close)
Urovant Sciences Ltd (NASDAQ: UROV) (after the market close)

 

Related Articles (XBI + IBB)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Offerings FDA Top Stories Pre-Market Outlook Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com